Short-term antibody response and tolerability of one dose of BNT162b2 vaccine in patients receiving hemodialysis
Rémi Goupil, Mehdi Benlarbi, William Beaubien-Souligny, Annie-Claire Nadeau-Fredette, Chatterjee Debashree, Guillaume Goyette, Caroline Lamarche, Alexander Tom, Andrés Finzi, View ORCID ProfileRita S. Suri on behalf of the Réseau Rénal Québécois (Quebec Renal Network) COVID-19 Study Investigators
doi: https://doi.org/10.1101/2021.03.30.21254652
Rémi Goupil
1Hôpital du Sacré-Cœur de Montréal, Montréal, QC, Canada
MD, MScMehdi Benlarbi
2Centre de Recherche du CHUM, Montréal, QC, Canada
BSc (cand)William Beaubien-Souligny
2Centre de Recherche du CHUM, Montréal, QC, Canada
MD, MScAnnie-Claire Nadeau-Fredette
3Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada
MD, MScChatterjee Debashree
2Centre de Recherche du CHUM, Montréal, QC, Canada
PhDGuillaume Goyette
2Centre de Recherche du CHUM, Montréal, QC, Canada
PhDCaroline Lamarche
3Centre de recherche de l’Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada
MD, MScAlexander Tom
4Research Institute of the McGill University Health Center, Montreal, QC, Canada
BScAndrés Finzi
2Centre de Recherche du CHUM, Montréal, QC, Canada
5Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC, Canada
6Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada
PhDRita S. Suri
2Centre de Recherche du CHUM, Montréal, QC, Canada
5Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC, Canada
7Department of Medicine, McGill University, Montreal, QC, Canada
MD, MScArticle usage
Posted April 01, 2021.
Short-term antibody response and tolerability of one dose of BNT162b2 vaccine in patients receiving hemodialysis
Rémi Goupil, Mehdi Benlarbi, William Beaubien-Souligny, Annie-Claire Nadeau-Fredette, Chatterjee Debashree, Guillaume Goyette, Caroline Lamarche, Alexander Tom, Andrés Finzi, Rita S. Suri
medRxiv 2021.03.30.21254652; doi: https://doi.org/10.1101/2021.03.30.21254652
Short-term antibody response and tolerability of one dose of BNT162b2 vaccine in patients receiving hemodialysis
Rémi Goupil, Mehdi Benlarbi, William Beaubien-Souligny, Annie-Claire Nadeau-Fredette, Chatterjee Debashree, Guillaume Goyette, Caroline Lamarche, Alexander Tom, Andrés Finzi, Rita S. Suri
medRxiv 2021.03.30.21254652; doi: https://doi.org/10.1101/2021.03.30.21254652
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2253)
- Dermatology (199)
- Emergency Medicine (368)
- Epidemiology (11542)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3539)
- Geriatric Medicine (336)
- Health Economics (611)
- Health Informatics (2283)
- Health Policy (909)
- Hematology (333)
- HIV/AIDS (741)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (385)
- Neurology (3322)
- Nursing (189)
- Nutrition (504)
- Oncology (1747)
- Ophthalmology (521)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (221)
- Palliative Medicine (66)
- Pathology (434)
- Pediatrics (997)
- Primary Care Research (398)
- Public and Global Health (5966)
- Radiology and Imaging (1213)
- Respiratory Medicine (806)
- Rheumatology (367)
- Sports Medicine (309)
- Surgery (383)
- Toxicology (50)
- Transplantation (169)
- Urology (142)